Logo.png
Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022 08:00 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., May 18, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a...
Logo.png
Cocrystal Pharma to Present at the Noble Capital Markets’ NobleCon18 Conference
April 14, 2022 08:00 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., April 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a...
Logo.png
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
March 23, 2022 16:05 ET | Cocrystal Pharma, Inc.
Commenced enrollment in Phase 1 trial with orally administered, broad-spectrum antiviral agent CC-42344 for the treatment of pandemic and seasonal influenza AAdvanced COVID-19 programs with the goal...
Logo.png
Cocrystal Pharma to Participate in Upcoming Investment Conferences
March 03, 2022 08:00 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., March 03, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in two upcoming investment conferences as follows: Q1 Investor...
Logo.png
Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter
June 23, 2021 08:00 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., June 23, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
CocrystalPharmaInc.jpg
Cocrystal Pharma to Present at the 2019 Cantor Global Healthcare Conference
September 26, 2019 08:05 ET | Cocrystal Pharma, Inc.
- Presentation on Friday, October 4th at 1:45 PM ET - BOTHELL, WA, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage...